Walleye Capital’s Corvus Pharmaceuticals CRVS Stock Holding History

Walleye Capital’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-15,080	Closed	-$25K	–	2423
2022 Q1	$25K	Sell	15,080 -11,502	-43%	-$21.1K	﹤0.01%	1923
2021 Q4	$64K	Buy	+26,582	New	+$103K	﹤0.01%	1753

Other funds holding CRVS

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Walleye Capital's CRVS Position: Q2 2022 in Review

Walleye Capital sold out of Corvus Pharmaceuticals (CRVS) in Q2 2022, closing a stake of 15,080 shares — an estimated $25K sold.

Walleye Capital first reported a position in CRVS in Q4 2021 and held it in 2 quarters. The position peaked at $64K in Q4 2021. 47 funds tracked by Wall St. Rank hold CRVS as of Q2 2022.

Walleye Capital reported no remaining Corvus Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Walleye Capital sold 15,080 Corvus Pharmaceuticals shares in Q2 2022, an estimated $25K.
Walleye Capital first reported a position in Corvus Pharmaceuticals in Q4 2021 and held it in 2 quarters.
Walleye Capital's Corvus Pharmaceuticals position peaked at $64K in Q4 2021.
47 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2022.

Based on Walleye Capital's 13F filing for Q2 2022, filed 8 Aug 2022.